Have MS Hospitalization Rates Declined? Have disease-modifying therapies for MS modified cost, hospitalization rate, or length of stay?
Tysabri/Natalizumab: A Review of Its Use in the Management of Relapsing-Remitting Multiple Sclerosis.
(Teriflunomide) was recently approved for treatment of MS & has
demonstrated clinical efficacy & safety in a number of large,
multicenter, phase III clinical trials. Furthermore, existing clinical
experience with its parent drug, leflunomide, provides indirect
long-term safety data. This review summarizes teriflunomide's
pharmacologic properties, pivotal clinical trials, and safety profile
& ends with a discussion of the role of teriflunomide in the context
of current and emerging MS treatment options.
Can Multiple Sclerosis Be Treated Surgically?
T-cell homeostasis in pediatric multiple sclerosis: Old cells in young patients.http://www.ncbi.nlm.nih.gov/pubmed/23911752
Premature immune senescence in children with MS: Too young to go steady.
MAPT Gene Rs1052553 Variant is not Associated with the Risk for Multiple Sclerosis
Siponimod for Relapsing-Remitting MS
Recycled Meds and New Approaches in Multiple Sclerosis
Active MS Is Associated With Accelerated Retinal Ganglion Cell/Inner Plexiform Layer Thinning
Spinal cord lesions and disability in Hispanics with multiple sclerosis.